Bioprocessing of Viral Vectors and Vaccines

点击翻译按钮获取中文摘要

The major accomplishments achieved by the chair during the previous term include: - Acceleration of influenza seed stocks generation from months to weeks to enable rapid vaccine manufacturing in response to pandemic situations using cell culture technology and reverse engineering.- Development and technology transfer of manufacturing process for adenovirus-vectored vaccine against Newcastle Disease infection for protection of livestock in Ethiopia. - Advanced process development of a Vero cell line production platform operated in suspension and serum free media for manufacturing of recombinant Vesicular Stomatitis Virus-vectored vaccine against Ebola, HIV and SARS-CoV-2 candidate vaccines.- Capacity building and Highly Qualified Perosonnel (HQP) training in Canada and abroad to support preparedness plans in response to emerging and re-emerging infectious diseases.Building on these impactful achievements, that are currently used by industry for accelerated development of vectored vaccines against COVID-19 pandemic, the proposed CRC Tier 1 research program in Bioprocess Sciences and Technology of Viral Vectors and Vaccines focuses on reverse engineering of complex biological systems and dynamics of cell/virus interaction to design advanced manufacturing processes for safe, efficacious and cost-effective vaccines and delivery systems for in-vivo gene editing. A system approach integrating 1) genome-scale re-design of viral and cellular biological platforms, 2) continuous process acceleration and intensification, 3) process analytical technologies and data sciences, to support the delivery of high-value medicines in response to emerging and re-emerging infectious diseases. The research program builds on long-lasting collaborations with industrial and institutional partners to support translation of novel technologies and support commercialization of high value viral-based products. The program is also designed to provide solid training for HQPs to meet the needs of the Canadian biomanufacturing industry and build sustained capacity in the strategic area of advanced vaccine manufacturing.